DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.
Article Details
- CitationCopy to clipboard
Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.
Nature. 2008 Nov 6;456(7218):66-72. doi: 10.1038/nature07485.
- PubMed ID
- 18987736 [ View in PubMed]
- Abstract
Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about 13,000 adults in the United States each year. The treatment of this disease has changed little in the past two decades, because most of the genetic events that initiate the disease remain undiscovered. Whole-genome sequencing is now possible at a reasonable cost and timeframe to use this approach for the unbiased discovery of tumour-specific somatic mutations that alter the protein-coding genes. Here we present the results obtained from sequencing a typical acute myeloid leukaemia genome, and its matched normal counterpart obtained from the same patient's skin. We discovered ten genes with acquired mutations; two were previously described mutations that are thought to contribute to tumour progression, and eight were new mutations present in virtually all tumour cells at presentation and relapse, the function of which is not yet known. Our study establishes whole-genome sequencing as an unbiased method for discovering cancer-initiating mutations in previously unidentified genes that may respond to targeted therapies.
DrugBank Data that Cites this Article
- Polypeptides
Name UniProt ID Receptor-type tyrosine-protein kinase FLT3 P36888 Details Multidrug resistance-associated protein 1 P33527 Details Urokinase-type plasminogen activator P00749 Details Serum paraoxonase/arylesterase 1 P27169 Details Dihydropyrimidine dehydrogenase [NADP(+)] Q12882 Details Cystic fibrosis transmembrane conductance regulator P13569 Details Aromatase P11511 Details Methylenetetrahydrofolate reductase (NADPH) P42898 Details Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial O14521 Details Melanocyte-stimulating hormone receptor Q01726 Details Leptin receptor P48357 Details Induced myeloid leukemia cell differentiation protein Mcl-1 Q07820 Details ATP-binding cassette sub-family C member 6 O95255 Details TGF-beta receptor type-1 P36897 Details Hepatocyte growth factor-regulated tyrosine kinase substrate O14964 Details Interleukin-1 receptor antagonist protein P18510 Details